Select region:

Clinical trials located in

Palermo

Palermo city is located in Italy. Currently, 20 clinical trials are being conducted in this city.

Palermo, the capital of Sicily, Italy, is steeped in history and culture. Founded by the Phoenicians in 734 BC, it has been a crossroads of civilizations for centuries. The city is renowned for its diverse architecture, reflecting Arab, Norman, Byzantine, and Baroque influences, notably in landmarks like the Palermo Cathedral and the Norman Palace. Palermo is also the birthplace of the Sicilian Mafia, a fact that has shaped its history and culture. The bustling markets, such as Ballarò and Vucciria, offer a glimpse into the vibrant local life and culinary traditions.

  • CT-EU-00112086

    To study the effectiveness of mitotane in preventing cancer recurrence in patients with adrenocortical carcinoma

    The ADIUVO trial is focused on understanding the effectiveness of a treatment called mitotane in patients who have undergone surgery for a rare type of adrenocortical cancer. This cancer has a high chance of coming back after surgery, and previous research suggests that mitotane may help reduce this risk. However, it is important to confirm these results in a study in which patients are randomly assigned to receive mitotane or no additional treatment after surgery. This is particularly important for patients whose cancer is at low or intermediate risk of coming back because doctors need to be sure that the benefits of mitotane outweigh any side effects.

    In this study, the goal is to see if mitotane can help patients live longer without their cancer coming back. Doctors will also assess patients’ overall life expectancy, quality of life and any side effects that may occur as a result of treatment. In addition, they will check whether mitotane levels in the blood influence these results and whether there are differences in results depending on certain characteristics of the cancer.

    Treatment with mitotane will be started at a lower dose and gradually increased depending on your tolerability, with adjustments possible depending on blood levels and side effects. The main goal is to compare how long patients remain cancer-free after surgery, with particular emphasis on their overall well-being and any potential side effects of treatment.

    FranceGermanyItalyNetherlandsUnited Kingdom
  • Discovery of sorafenib and paclitaxel in the treatment of advanced adrenal cancer

    This clinical trial is focused on patients with Adrenocortical Carcinoma (ACC), a type of cancer that affects the adrenal glands. If a patient has ACC that has spread or cannot be removed by surgery, and if previous chemotherapy treatments haven’t worked, this study might be an option for them. The trial is testing a combination of two treatments: Sorafenib and Paclitaxel. Sorafenib is a pill taken twice a day, and Paclitaxel is given through an IV once a week. The goal is to see if this combination can help stop the cancer from growing.

    The main thing the doctors are looking to find out is if the cancer stops progressing in the first 4 months of treatment. They’re also interested in how long the treatment works, how it impacts the cancer, and any side effects that might be experienced. Another important part of the study is looking at how the treatment impacts the patient’s quality of life.

    The patient’s health will be closely monitored throughout the study, with the first check-up after 8 weeks and then every 12 weeks. This trial is a chance to try a new treatment combination that’s designed specifically for ACC patients who need more options.

    Italy
  • Continued Parsaclisib treatment for B-cell cancer patients

    This is a phase II clinical trial focused on providing continuation of treatment with a drug called parsaclisib to people diagnosed with B-cell malignancies. The main goal of this study is to expand the treatment regimen established in the previous study. Study participants will receive parsaclisib as a stand-alone therapy (monotherapy) or in combination with other therapeutic agents, which may include itacitinib, ruxolitinib or ibrutinib. The study aims to facilitate participants’ ongoing care and contribute to the broader field of medical research by collecting data on the effectiveness and safety of prolonged use of parsaclisib.

    AustriaBelgiumCzechiaDenmarkFranceHungaryItalyNorwayPolandSpainSwedenUnited Kingdom
  • Exploring the safety of seladelpar in treating primary biliary cholangitis

    This is a long-term study on a drug named seladelpar for people with a liver disease called Primary Biliary Cholangitis (PBC). The main goal is to see if this drug is safe and easy for patients with PBC to use over a long period. A secondary goal is to see if seladelpar can effectively treat PBC and improve the patient’s quality of life. The study will track a few things, like if there are changes in the patient’s liver health which may lead to hospitalization or if the patient’s liver enzymes like alkaline phosphate and bilirubin level normalize or not after taking this drug.

    AustriaBelgiumCzechiaFranceGermanyGreeceHungaryItalyNetherlandsPolandRomaniaSpainUnited Kingdom
  • Study on new combination therapy for aggressive lymphoma

    This study is about a less common but severe form of cancer known as Diffuse Large B-Cell Lymphoma (DLBCL). It is testing if a new medication called epcoritamab, given with a mix of other commonly used cancer medicines, can help control the disease better. These other medicines include rituximab, cyclophosphamide, doxorubicin hydrochloride, vincristine, and prednisone, which are often collectively referred to as R-CHOP. The study includes about 900 adults from around the world who have recently been diagnosed with this type of lymphoma. They will be split into two groups. One group will get epcoritamab with R-CHOP and then continue with epcoritamab. The other group will get R-CHOP followed by rituximab. Doctors will carefully watch for changes in the disease and for any side effects. There will be many checks on health, including medical exams, blood tests, questionnaires, and monitoring of any side effects.

    AustriaBelgiumBulgariaCzechiaDenmarkFranceGreeceHungaryItalyNetherlandsPolandPortugalSpainSweden
  • Assessing imatinib inhalation therapy for pulmonary arterial hypertension

    This clinical study aims to evaluate the safety and efficacy of an inhaled treatment called imatinib (AV-101) for patients with Pulmonary Arterial Hypertension (PAH). The trial is divided into two parts: Phase 2b and Phase 3. In Phase 2b, researchers will test three doses of AV-101 to identify the optimal dose for Phase 3. They will check this by measuring the resistance of the lung vessels — less resistance means the medicine is working. In the following Phase 3, the primary outcome will be the change in the 6-minute walk distance after 24 weeks of treatment compared to a placebo. Participants must be between 18 and 75 years old, have a diagnosis of PAH, and meet specific criteria regarding their disease severity and concomitant therapy.

    AustriaBelgiumCzechiaFranceGermanyGreeceItalyNetherlandsPolandPortugalSpainSwedenUnited Kingdom
  • Testing a new combination therapy with acalabrutinib for a specific type of lymphoma

    This clinical trial is investigating a new combination therapy for diffuse large B-cell lymphoma, a type of lymphoma. The treatment combines Acalabrutinib, a targeted therapy drug, with R-CHOP, a chemotherapy mix consisting of rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone, a standard chemotherapy regimen. The aim of the study is to evaluate the safety and effectiveness of this combination in improving patient outcomes. It focuses on patients who have not been previously treated for lymphoma. The study aims to find better treatment strategies for this particular type of lymphoma.

    AustriaBelgiumCzechiaFranceGermanyItalyPolandPortugalSpain
  • Examining new drug impact on nonalcoholic fatty liver disease

    This study is evaluating GSK4532990 in adults with advanced non-alcoholic steatohepatitis (NASH). This is a Phase 2b trial comparing GSK4532990 with placebo, focusing on liver fibrosis and inflammation relief. The study will include high-dose, low-dose and placebo groups and will include 246 participants. Primary outcomes are improvement in histologic fibrosis and resolution of NASH at 52 weeks. Secondary outcomes include changes in liver and fat markers.

    BelgiumFranceGreeceItalySpainUnited Kingdom
  • Study on the efficacy of pirtobrutinib for mantle cell lymphoma

    This clinical trial is designed for patients diagnosed with mantle cell lymphoma (MCL), a type of blood cancer. The primary objective of the study is to assess the efficacy of a new drug called pirtobrutinib in comparison to other similar drugs that have received approval from the U.S. Food and Drug Administration (FDA). Participants may be involved in the study for a duration of two years or more, contingent on their condition not worsening. The trial will categorize patients into two groups: one receiving pirtobrutinib, and the other receiving either ibrutinib, acalabrutinib, or zanubrutinib, which are existing FDA-approved drugs for this condition. Throughout the study, the participants’ health condition, symptoms, and any side effects will be closely monitored. Additionally, the effectiveness of the treatments will be measured by evaluating the eventual survival rates of the patients.

    AustriaBelgiumCzechiaDenmarkFranceGermanyHungaryItalyNetherlandsPolandPortugalSpainUnited Kingdom
  • Evaluating efinopegdutide treatment for nonalcoholic steatohepatitis

    This clinical trial explores a new treatment for non-alcoholic steatohepatitis (NASH), a liver condition. It tests the safety and effectiveness of efinopegdutide, a medication administered through weekly injections. Participants, diagnosed with NASH but not severe liver damage, will receive either the medication or a placebo. The study aims to improve liver health and assess potential side effects. It prioritizes participant safety and involves regular health monitoring.

    AustriaBelgiumCzechiaFranceHungaryItalyPortugalSpainUnited Kingdom
  • Examining long-term use of osimertinib in treating lung cancer

    This study is investigating a drug known as osimertinib. This includes people who have had successful surgery to remove a type of lung cancer called NSCLC. This cancer is caused by a mutation in a protein called EGFR. The aim of this study is to see if osimertinib can prevent the cancer from coming back within 5 years. The goal is also to ensure the drug’s safety for patients. Patients will receive the drug regardless of whether they received chemotherapy after surgery or not. Here are some of the issues investigators in this study will look at: how long it takes for the cancer to come back, if at all; how many people are alive without the disease after 3, 4 and 5 years; and how long people live after starting the drug. Additionally, a key part of the study is monitoring for any potential side effects.

    ItalySpainUnited Kingdom
  • Testing inhaled imatinib for pulmonary arterial hypertension

    This study is about a new medicine called imatinib (AV-101) which you breathe in as a dry powder. It’s for people who have a health problem called Pulmonary Arterial Hypertension (PAH) – when blood pressure is too high in the arteries that go from the heart to the lungs. The imatinib study will go through two stages. In the first stage, the researchers will try three different amounts of the medicine to find the best one. It will be based on how much it can reduce the resistance in the blood flow in the lungs. In the second stage, they it will be seen how far patients can walk in 6 minutes after taking the medicine for 24 weeks. The study also uses scoring systems to measure how much risk or symptoms a patient has. A higher score means more risk or symptoms.

    AustriaBelgiumCzechiaFranceGermanyGreeceItalyNetherlandsPolandPortugalSpainSwedenUnited Kingdom
  • Comparison study of two melanoma treatments containing pembrolizumab

    This study compares two treatments for a type of skin cancer known as high-risk melanoma. Participants of this study have previously had this cancer surgically removed. The tested treatments are pembrolizumab with vibostolimab, and pembrolizumab alone. The aim is to find out which treatment is better at preventing the melanoma from returning or spreading to other parts of the body. Even after a successful surgery, some cancer cells may be left behind which could result in the cancer returning. The study is measuring the time it takes for the cancer to return and the time it takes for the cancer to spread far from where it started.

    AustriaBelgiumFranceGermanyItalyPolandSpainSwedenUnited Kingdom
  • Testing gefurilimab treatment in patients with myasthenia gravis

    This study is looking at a potential treatment for a disease called generalized myasthenia gravis (gMG) in adults. It’s called gefurulimab (ALXN1720). For our study, researchers will divide participants into two groups, each of which will be treated differently. One group will receive the new drug. Importantly, the researchers conducting the study will not know who received which treatment. This ensures the fairness and accuracy of the results. Participants’ health will be closely monitored to ensure that ALXN1720 is safe. The main goal is to check whether new mediations are effective. It will be measured by checking whether patients’ condition has improved compared to when the study started. This will take approximately 26 weeks.

    AustriaDenmarkFranceGermanyItalyNetherlandsPolandPortugalSpainUnited Kingdom
  • Testing the effectiveness of a new drug compared with standard therapy in the treatment of asthma

    This medical research is a year-long study that tests a new asthma medication, called GSK3511294 (Depemokimab), against two other asthma medicines, Mepolizumab and Benralizumab. The trial is intended for teens and adults who have a severe form of asthma called ‘eosinophilic phenotype.’ The aim is to see if switching to GSK3511294 from Mepolizumab or Benralizumab keeps the severity and frequency of asthma attacks under control equally or better. Participants will keep taking their regular non-biological asthma medications throughout the trial. The study will look at the number of severe asthma attacks a patient experiences in a year, which is defined here as any worsening of asthma requiring steroids, a hospital visit, or an emergency room trip. They will also check for changes in their quality of life and their asthma control using questionnaires, and measure the capacity of their lungs with a breathing test.

    AustriaFinlandFranceGermanyItalyNetherlandsNorwayPolandPortugalSloveniaSpainSwedenUnited Kingdom
  • Testing zamaglutenase for gluten breakdown in celiac disease treatment

    This study focuses on a medicine called zamaglutenase (TAK-062) that may help people with celiac disease. Celiac disease is a condition where the body can’t process gluten, which is found in wheat, rye, and barley. When people with celiac disease eat gluten, their immune system reacts by damaging the small intestine. TAK-062 is meant to break down the gluten in a person’s stomach, possibly helping the body cope better. The study needs around 357 volunteers, who will be split into two groups at random. Both groups will involve adults over 18 years of age. The first group will get a placebo (a medicine-like substance with no actual medicine) and a gluten bar, and the other group will get a dose of TAK-062 alongside the gluten bar. After some time, a committee will check the results of the first group. Depending on what they find, the study may then include teenagers, and the second group will start. Just like any medicine, TAK-062 may or may not cause side effects. Even seemingly unrelated health problems that happen during the study are important, as they could be linked to the medicine, even if it’s not clear at first. This study aims to find clear and truthful results about how TAK-062 works for people with celiac disease.

    BelgiumFranceItalyPolandSpainUnited Kingdom
  • Durvalumab and chemotherapy in advanced biliary tract cancer treatment

    This study is testing the effectiveness and safety of durvalumab, a biological drug, combined with various gemcitabine-based chemotherapy regimens in patients with advanced biliary tract cancers (aBTC). The trial will include four periods: a screening phase, a treatment phase of up to 8 cycles of chemotherapy with durvalumab, a maintenance phase with durvalumab alone or in combination with chemotherapy, and a follow-up phase for safety and survival. Patients will receive durvalumab via intravenous infusion every 3 or 4 weeks, along with chemotherapy every 3 or 2 weeks for a maximum of 8 cycles. The study’s primary goal is to observe any severe adverse events possibly related to the treatment. Secondary goals include measuring overall survival, response rate, progression-free survival, and other factors.

    FranceGermanyItalySpain
  • Effects of new treatment on nonalcoholic steatohepatitis

    This study tests a new medicine, AZD2693, through skin injections in adults with a special type of liver disease called non-cirrhotic non-alcoholic steatohepatitis (NASH) with fibrosis. Participants, who have a specific genetic risk (PNPLA3 148M allele), will either get AZD2693 or a placebo. The study, involving 180 people, checks if AZD2693 can help reduce liver problems without causing further damage. It runs for about a year, looking at liver health and any side effects from the medicine.

    GermanyItalySpain
  • Study on the benefits of combined therapy for high-risk non-muscle invasive bladder cancer

    This research study is focused on investigating the safety and effectiveness of a medication called Pembrolizumab (MK-3475) when combined with Bacillus Calmette-Guerin (BCG) treatment in individuals with high-risk bladder cancer that has not spread to the muscle. The study involves two groups of patients: those who have not responded well to BCG alone and those who have not received BCG previously. For the first group, the primary objective is to determine if the combination of Pembrolizumab and BCG is more effective than BCG alone in eliminating their cancer. For the second group, the goal is to assess whether the combination therapy improves the likelihood of survival without any cancer-related events compared to BCG alone.

    AustriaBelgiumFranceGermanyGreeceHungaryItalyNetherlandsNorwayPolandPortugalSpainUnited Kingdom
  • Study of alpelisib and fulvestrant for advanced breast cancer treatment

    This trial is looking at the effects of the combined use of two drugs, alpelisib and fulvestrant, in treating patients who have advanced breast cancer. The cancer should be HR-positive and HER2-negative, and have a specific mutation (PIK3CA). If the patients already underwent certain other treatments like CDK4/6 Inhibitors and aromatase Inhibitors, but the cancer has progressed, they could join this trial. Doctors will be able to compare the results of patients taking alpelisib and fulvestrant together, with those taking fulvestrant with a placebo, They aim to check which combination works better in delaying the advance of cancer or in improving a patient’s life duration.

    BelgiumBulgariaCzechiaDenmarkFinlandFranceGermanyGreeceHungaryItalyPolandPortugalRomaniaSlovakiaSpain

See more clinical trials in other cities in Italy:

.